NoneGOLDEN, Colo.--(BUSINESS WIRE)--Nov 22, 2024-- Golden Minerals Company (“Golden Minerals”, “Golden” or the “Company”) (NYSE-A: AUMN and TSX: AUMN) today announced it has closed on the sale of its Yoquivo gold-silver project (located in Chihuahua State, Mexico) (the “Yoquivo Project”). The buyer is Advance Metals Limited (ASX: AVM) (“AVM”), an ASX-listed entity focused on the acquisition, discovery, and advancement of high-quality metals projects. Pursuant to the sales agreement that the Company announced last month ( Press Release - Golden Minerals to Sell Yoquivo Project ), AVM has purchased 100% of the Yoquivo Project from Minera de Cordilleras S. de R.L. de C.V., a wholly owned subsidiary of Golden Minerals, for total consideration of US$570,000, which was paid in cash, plus value added tax (“VAT”), as follows: Golden Minerals will finalize the transfer of the Yoquivo concessions upon establishment of a Mexican subsidiary by AVM. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”), including statements regarding the Company finalizing the transfer of the Yoquivo concessions upon establishment of a Mexican subsidiary by AVM. These statements are subject to risks and uncertainties including receipt of regulatory approvals required to finalize the Transaction; increases in costs and declines in general economic conditions; changes in political conditions, in tax, royalty, environmental and other laws in the United States, Mexico or Argentina and other market conditions; and fluctuations in silver and gold prices. Golden assumes no obligation to update this information. Additional risks relating to Golden may be found in the periodic and current reports filed with the Securities & Exchange Commission by Golden, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. For additional information please visit http://www.goldenminerals.com/ . View source version on businesswire.com : https://www.businesswire.com/news/home/20241122446744/en/ CONTACT: Golden Minerals Company (303) 839-5060 KEYWORD: NORTH AMERICA UNITED STATES MEXICO CANADA CENTRAL AMERICA COLORADO INDUSTRY KEYWORD: MINING/MINERALS NATURAL RESOURCES SOURCE: Golden Minerals Company Copyright Business Wire 2024. PUB: 11/22/2024 05:00 PM/DISC: 11/22/2024 05:02 PM http://www.businesswire.com/news/home/20241122446744/en
Turkish-Australian celebrity chef Somer Sivrioglu sentenced to prison in IstanbulWASHINGTON — If there’s a theme among President-elect Donald Trump’s health Cabinet picks, it’s this: The vast majority were critics of how the Biden administration handled COVID-19. The pandemic upended Americans’ perspective on public health and health care delivery, both throughout the United States and among Republican lawmakers. Policy experts say that change is evident in Trump’s selections to lead major U.S. health agencies. That change is particularly notable in Trump’s pick for secretary of Health and Human Services, Robert F. Kennedy Jr., a vaccine skeptic who has been critical of the federal government’s pandemic response. Trump and Republicans have praised Kennedy for bucking conventional thinking when it comes to public health, even though many of Kennedy’s theories and proposals are not backed by science. Throughout the COVID-19 pandemic, Kennedy advocated against vaccinating kids against the coronavirus. He also led the anti-vaccination group Children’s Health Defense beginning in 2018. As Trump’s presumptive HHS secretary nominee, Kennedy worked with the Trump team to pick the leaders of the Centers for Disease Control and Prevention, the Centers for Medicare and Medicaid, the Food and Drug Administration and the National Institutes of Health. Former Rep. Dave Weldon, Trump’s selection to head the CDC, is also a vaccine skeptic. Mehmet Oz, known more commonly as “Dr. Oz,” Trump’s choice to head CMS, promoted use of the anti-malarial drug hydroxychloroquine to treat COVID-19. FDA commissioner pick Marty Makary promoted herd immunity to stop the virus, as did Trump’s choice to lead the NIH, Jay Bhattacharya. Taken as a whole, the picks reflect a deep skepticism toward the recommendations of the very agencies these men have been tapped to lead. Trust in public health institutions plummeted in the wake of the pandemic, particularly among Republicans, according to polling, and virus prevention measures like wearing a face mask on an airplane or getting a routine vaccination have morphed into political actions in many parts of the United States. “There was a lot of misinformation, uncertain information,” Sen. Shelley Moore Capito, R-W.Va., said of the COVID-19 pandemic response. “In the end, when you looked at what the benefits were, the benefits were not as large as promised and some people were penalized. So I’m sure that’s reflected in [Trump’s] Cabinet choices.” But as Republicans cheer these changes to the public health sector, Democrats and medical institutions are concerned about health misinformation and how that could impact the American health care system, which spends roughly $4.5 trillion per year and accounts for 17.3 percent of the nation’s gross domestic product. On the campaign trail, Trump won voters by promising to buck the system. But public health experts warn that moving too far from the medical establishment and rejecting scientific data could have disastrous consequences. A look at other key Trump health picks and their records on COVID-19: Mehmet Oz, CMS Oz has long been criticized for his controversial views on public health. The pandemic was no exception. The Daytime Emmy award winner served as an informal adviser during the first Trump administration, promoting the use of hydroxychloroquine to treat COVID-19 early in the pandemic. He reportedly tried to persuade the president’s advisers to accelerate approval of the drug for use against COVID-19, even though at the time it had not been tested against the virus. Later, the FDA and infectious disease doctors found the antimalarial would not treat the virus. Oz also urged Trump administration officials to back a study he offered to fund at Columbia University Medical Center about the impacts of the antimalarial on COVID-19 patients, according to the House Select Subcommittee on the Coronavirus Pandemic. Sign up to get our free daily email of the biggest stories! In April 2020, Oz said on Fox News that reopening schools would be worth it, even if it led to increased deaths. He later retracted the statement. Marty Makary, FDA Like Kennedy, Makary has publicly questioned the broad use of COVID-19 vaccines and vaccine mandates. But unlike Kennedy and many others in Trump’s health Cabinet, Makary was an early advocate of masking to prevent the spread of the virus and restricting air travel. The Johns Hopkins surgeon and author publicly opposed COVID-19 booster shots and promoted natural immunity over vaccinations. He went as far as arguing that the federal government censored pandemic data on natural immunity in an attempt to get more people vaccinated. But Makary also promoted early vaccination strategies to protect those most at risk for severe disease, such as getting single doses of vaccines to as many people as possible before allowing people to go back for a second dose of the shot. In late 2020, he criticized the FDA for not moving fast enough to approve mRNA vaccines. Jay Bhattacharya, NIH A Stanford physician and professor, Bhattacharya made a name for himself as a skeptic who opposed COVID-19 lockdowns and vaccine mandates. He also promoted herd immunity, the concept that low-risk people should live their lives normally and build up resistance to COVID-19 through infection while only high-risk individuals took precautions. In October 2020, Bhattacharya co-authored the controversial “Great Barrington Declaration,” an open letter advocating against virus prevention measures with the hopes of quickly obtaining herd immunity. Both the World Health Organization and leading academic and public health organizations condemned the letter, with the American Public Health Association and other health organizations signing a letter calling it a “wrong-headed proposal masquerading as science” and arguing that the declaration would lead to preventable deaths. Dave Weldon, CDC Weldon, a physician who represented Florida in the U.S. House of Representatives from 1995 through 2009, has routinely questioned the links between vaccines and autism throughout his career. He does not specialize in infectious diseases and has never formally worked in public health, having spent his career as a military doctor, internist and politician. In 2007, Weldon introduced a bill that would remove vaccine safety research from the CDC’s domain and house it in a separate HHS agency. Although the bill didn’t advance, some privately worry it’s indicative of the way he’d strip down the public health agency. Former acting CDC Director Richard Besser said he’s concerned about Weldon’s lack of public health credentials and suspects he was nominated to the post largely because his vaccine skepticism aligns with Kennedy’s views. “What we’re seeing with a number of these nominations is a continuation of that politicization [of public health], where you know people coming in who are saying public health is the problem, not the solution,” Besser said.
How to unlock Flea Market in PalworldWALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of December 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase 27,445 shares of Apellis’ common stock and 28,630 restricted stock units (RSUs). The options have an exercise price of $35.42, which is equal to the closing price of Apellis’ common stock on December 2, 2024, the grant date of the options. One-fourth of the shares underlying the employee options will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the employee options will vest monthly, such that the shares underlying the options granted to the employees will be fully vested on the fourth anniversary of the grant date, subject to the employees’ continued employment with Apellis on such vesting dates. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn . Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding plans to submit applications for regulatory approval for the treatment of patients with C3G and IC-MPGN. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether systemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; and any other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Media Contact: Tracy Vineis media@apellis.com 617-420-4839 Investor Contact: Meredith Kaya meredith.kaya@apellis.com 617.599.8178
“Rainbow Six,” “Captain Planet” Still In DevelopmentDeutsche Bank appointed as depositary bank for the sponsored American Depositary Receipt program of Pony AI Inc.
Chhattisgarh: Businessman Threatens Female GST Officer, Claims Backing Of Finance Minister; FIR Filed
CHANDLER, Ariz., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, provided lower updated revenue guidance for the December 2024 quarter and announced manufacturing restructuring plans. "In the first two weeks of my newly appointed role as Interim CEO and President, I have done a deep dive into the operations of the Company and determined that certain actions are necessary. I want to clarify for investors that I plan to stay in this role, even though the title is interim, for as long as it is necessary, so there is no definitive timeline for my successor," said Steve Sanghi, Microchip's CEO, President and Chair of the Board. Mr. Sanghi continued, "We indicated in our November 2, 2024 earnings call that significant turns orders were required to achieve the midpoint of our December 2024 quarter revenue guidance. Those turns orders have been slower than anticipated and we now expect our December 2024 revenue to be close to the low end of our original guidance which is $1.025 billion." Mr. Sanghi added, "With inventory levels high and having ample capacity in place, we have decided to shut down our Tempe wafer fabrication facility that we refer to as Fab 2. Many of the process technologies that run in Fab 2 also run in our Oregon and Colorado factories, which both have ample clean room space for expansion. We expect to be able to shut down Fab 2 in the September 2025 quarter at which time we expect that it will generate annual cash savings of approximately $90 million. Due to the high inventory of the products which are manufactured in Fab 2, we do not expect to see P&L savings from the shutdown until the start of the June 2026 quarter based on a First-In First-Out basis. We expect that the Fab 2 closure will begin to help us moderate our inventory levels beginning in the March 2025 quarter. We anticipate near-term restructuring costs to be between $3 million and $8 million from these actions, and it is possible that we could incur other restructuring and shut-down costs in the future of up to an additional $15 million. The estimates of the restructuring costs will be refined over time as more information becomes available." Mr. Sanghi concluded, "I want to ensure investors of my confidence in the long-term growth and profitability of Microchip. Our design-in momentum continues to remain strong, driven by our Total System Solutions strategy and key market megatrends. The fab restructuring is a big step in right-sizing our manufacturing footprint, and we will continue to evaluate any further actions that are required to position Microchip for outsized growth and financial performance." Microchip will be participating in and presenting at the UBS Global Technology and AI Conference on December 3 and 4, 2024. Cautionary Statement: The statements in this release relating to Mr. Sanghi planning to stay in the CEO and President role for as long as it is necessary, no definitive timeline for his successor, that turns orders have been slower than anticipated and that we now expect our December 2024 revenue to be close to the low end of our original guidance which is $1.025 billion, that we have ample capacity in place, that our Oregon and Colorado factories both have ample clean room space for expansion, that we expect to be able to shut down Fab 2 in the September 2025 quarter at which time it is expected to generate annual cash savings of approximately $90 million, that we do not expect to see P&L savings from the shutdown until the start of the June 2026 quarter, that we expect that the Fab 2 closure will begin to help us moderate our inventory levels beginning in the March 2025 quarter, that we anticipate near-term restructuring costs to be between $3 million and $8 million, that is is possible that we could incur other restructuring and shut-down costs of up to an additional $15 million, ensuring investors of my confidence in the long-term growth and profitability of Microchip, that our design-in momentum continues to remain strong driven by our Total System Solutions strategy and key market megatrends, that the fab restructuring is a big step in right sizing our manufacturing footprint, that we will continue to evaluate any further actions that are required to position Microchip for outsized growth and financial performance are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause our actual results to differ materially, including, but not limited to: any continued uncertainty, fluctuations or weakness in the U.S. and world economies (including China and Europe) due to changes in interest rates, high inflation, actions taken or which may be taken by the Biden administration or the U.S. Congress or by the incoming Trump administration and the incoming U.S. Congress, monetary policy, political, geopolitical, trade or other issues in the U.S. or internationally (including the military conflicts in Ukraine-Russia and the Middle East), further changes in demand or market acceptance of our products and the products of our customers and our ability to respond to any increases or decreases in market demand or customer requests to reschedule or cancel orders; the mix of inventory we hold, our ability to satisfy any short-term orders from our inventory and our ability to effectively manage our inventory levels; the impact that the CHIPS Act will have on increasing manufacturing capacity in our industry by providing incentives for us, our competitors and foundries to build new wafer manufacturing facilities or expand existing facilities; the amount and timing of any incentives we may receive under the CHIPS Act, the impact of current and future changes in U.S. corporate tax laws (including the Inflation Reduction Act of 2022 and the Tax Cuts and Jobs Act of 2017), foreign currency effects on our business; changes in utilization of our manufacturing capacity and our ability to effectively manage our production levels to meet any increases or decreases in market demand or any customer requests to reschedule or cancel orders; the impact of inflation on our business; competitive developments including pricing pressures; the level of orders that are received and can be shipped in a quarter; our ability to realize the expected benefits of our long-term supply assurance program; changes or fluctuations in customer order patterns and seasonality; our ability to effectively manage our supply of wafers from third party wafer foundries to meet any decreases or increases in our needs and the cost of such wafers, our ability to obtain additional capacity from our suppliers to increase production to meet any future increases in market demand; our ability to successfully integrate the operations and employees, retain key employees and customers and otherwise realize the expected synergies and benefits of our acquisitions; the impact of any future significant acquisitions or strategic transactions we may make; the costs and outcome of any current or future litigation or other matters involving our acquisitions (including the acquired business, intellectual property, customers, or other issues); the costs and outcome of any current or future tax audit or investigation regarding our business or our acquired businesses; fluctuations in our stock price and trading volume which could impact the number of shares we acquire under our share repurchase program and the timing of such repurchases; disruptions in our business or the businesses of our customers or suppliers due to natural disasters (including any floods in Thailand), terrorist activity, armed conflict, war, worldwide oil prices and supply, public health concerns or disruptions in the transportation system; and general economic, industry or political conditions in the United States or internationally. For a detailed discussion of these and other risk factors, please refer to Microchip's filings on Forms 10-K and 10-Q. You can obtain copies of Forms 10-K and 10-Q and other relevant documents for free at Microchip's website ( www.microchip.com ) or the SEC's website ( www.sec.gov ) or from commercial document retrieval services. Stockholders of Microchip are cautioned not to place undue reliance on our forward-looking statements, which speak only as of the date such statements are made. Microchip does not undertake any obligation to publicly update any forward-looking statements to reflect events, circumstances or new information after this December 2, 2024 press release, or to reflect the occurrence of unanticipated events. About Microchip: Microchip Technology Incorporated is a leading provider of smart, connected and secure embedded control solutions. Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs, which reduce risk while lowering total system cost and time to market. Our solutions serve approximately 116,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality. For more information, visit the Microchip website at www.microchip.com . Note: The Microchip name and logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies. INVESTOR RELATIONS CONTACT: J. Eric Bjornholt, Senior Vice President and CFO (480) 792-7804 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's the diagnosis for ASX healthcare shares in 2025?Sportscaster Greg Gumbel dies from cancer at age 78Illawarra beach takes centre stage in national surf safety ad campaign
None
By ROB GILLIES, Associated Press TORONTO (AP) — Prime Minister Justin Trudeau told Donald Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products , a Canadian minister who attended their recent dinner said Monday. Trump threatened to impose tariffs on products from Canada and Mexico if they don’t stop what he called the flow of drugs and migrants across their borders with the United States. He said on social media last week that he would impose a 25% tax on all products entering the U.S. from Canada and Mexico as one of his first executive orders. Canadian Public Safety Minister Dominic LeBlanc, whose responsibilities include border security, attended a dinner with Trump and Trudeau at Trump’s Mar-a-Lago club on Friday. Trudeau requested the meeting in a bid to avoid the tariffs by convincing Trump that the northern border is nothing like the U.S. southern border with Mexico . “The prime minister of course spoke about the importance of protecting the Canadian economy and Canadian workers from tariffs, but we also discussed with our American friends the negative impact that those tariffs could have on their economy, on affordability in the United States as well,” LeBlanc said in Parliament. If Trump makes good on his threat to slap 25% tariffs on everything imported from Mexico and Canada, the price increases that could follow will collide with his campaign promise to give American families a break from inflation. Economists say companies would have little choice but to pass along the added costs, dramatically raising prices for food, clothing, automobiles, alcohol and other goods. The Produce Distributors Association, a Washington trade group, said last week that tariffs will raise prices for fresh fruit and vegetables and hurt U.S. farmers when the countries retaliate. Canada is already examining possible retaliatory tariffs on certain items from the U.S. should Trump follow through on the threat. After his dinner with Trump, Trudeau returned home without assurances the president-elect will back away from threatened tariffs on all products from the major American trading partner. Trump called the talks “productive” but signaled no retreat from a pledge that Canada says unfairly lumps it in with Mexico over the flow of drugs and migrants into the United States. “The idea that we came back empty handed is completely false,” LeBlanc said. “We had a very productive discussion with Mr. Trump and his future Cabinet secretaries. ... The commitment from Mr. Trump to continue to work with us was far from empty handed.” Joining Trump and Trudeau at dinner were Howard Lutnick, Trump’s nominee for commerce secretary, North Dakota Gov. Doug Burgum, Trump’s pick to lead the Interior Department, and Mike Waltz, Trump’s choice to be his national security adviser. Canada’s ambassador to the U.S., Kirsten Hillman, told The Associated Press on Sunday that “the message that our border is so vastly different than the Mexican border was really understood.” Hillman, who sat at an adjacent table to Trudeau and Trump, said Canada is not the problem when it comes to drugs and migrants. On Monday, Mexico’s president rejected those comments. “Mexico must be respected, especially by its trading partners,” President Claudia Sheinbaum said. She said Canada had its own problems with fentanyl consumption and “could only wish they had the cultural riches Mexico has.” Related Articles Flows of migrants and seizures of drugs at the two countries’ border are vastly different. U.S. customs agents seized 43 pounds of fentanyl at the Canadian border during the last fiscal year, compared with 21,100 pounds at the Mexican border. Most of the fentanyl reaching the U.S. — where it causes about 70,000 overdose deaths annually — is made by Mexican drug cartels using precursor chemicals smuggled from Asia. On immigration, the U.S. Border Patrol reported 1.53 million encounters with migrants at the southwest border with Mexico between October 2023 and September 2024. That compares to 23,721 encounters at the Canadian border during that time. Canada is the top export destination for 36 U.S. states. Nearly $3.6 billion Canadian (US$2.7 billion) worth of goods and services cross the border each day. About 60% of U.S. crude oil imports are from Canada, and 85% of U.S. electricity imports as well. Canada is also the largest foreign supplier of steel, aluminum and uranium to the U.S. and has 34 critical minerals and metals that the Pentagon is eager for and investing for national security.